A post hoc analysis of the DRCR.net Protocol I study demonstrated that the long-term outcomes of anti-VEGF treatment for diabetic macular edema can be predicted as early as after three monthly injections.
“We are very happy to know that we can predict the long-term outcome and make an early decision to move patients to another therapeutic strategy if they do not respond well to anti-VEGF therapy,” Albert J. Augustin, MD, told Ocular Surgery News.
Protocol I evaluated the effects of Lucentis (ranibizumab, Genentech) with prompt or deferred laser vs. triamcinolone (Read more...)
Uncategorized